Nkarta Inc (NKTX) - News Archive

Enhancing Treatment Options for Autoimmune and Hematologic Diseases: The Potential of NKX019 and NKX101 TherapiesThe field of immunotherapy has witnessed significant advancements in recent years, offering new hope for p...

Nkarta Strengthens Leadership Team with New President and Chief Medical OfficerJuly 16, 2024 - Nkarta, Inc. (Nasdaq: NKTX), a pioneering biopharmaceutical company specializing in engineered natural killer (NK) cell ther...

In a groundbreaking development, Nkarta, a leading biopharmaceutical company, has recently commenced the clinical trial of their innovative engineered NK cell therapy, NKX019, for the treatment of lupus nephritis. Ntrus...

Nkarta s Recent Underwritten Offering and Financial Performance Reflects Volatility in Biopharmaceutical SectorSOUTH SAN FRANCISCO, Calif., March 25, 2024 - Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company speci...

Clinical Pioneers or Adventurers?nn, San Francisco-based Nkarta, Inc., a company committed to creating pioneering treatments in the realm of cell therapies, has recently grabbed the spotlight at the American Society of...